Akbar Idhayadhulla, Mullaivendhan Janani, Ahamed Anis, Aljawdah Hossam M
Research Department of Chemistry, Nehru Memorial College (Affiliated Bharathidasan University) Puthanampatti 621007 Tamil Nadu India
Department of Botany and Microbiology, College of Science, King Saud University P. O. Box 2455 Riyadh 11451 Saudi Arabia.
RSC Adv. 2024 Jan 2;14(1):677-688. doi: 10.1039/d3ra06771h.
In this study, we developed a novel pyrazolo[3,4-]pyrazole derivative with antibacterial and antifungal activities that shows great potential for treating infectious diseases. To evaluate the binding affinity of 1AJ0 and 1AI9 proteins for developing potent antibacterial and antifungal compounds, we used the () leaf extract as the capping and reducing agent and reacted it with FeO and Cu(OAc) solutions to synthesize the -FeO-CuO nanocatalyst. The newly synthesized compounds were confirmed using Fourier transform infrared spectroscopy, transmission electron microscopy, UV-visible spectroscopy, and X-ray diffraction analyses. Antibacterial screening revealed that compound 1g was highly active against (MIC: 1 μg mL) and was much more effective than the standard ciprofloxacin. Compound 1b showed a higher antifungal activity than clotrimazole against (MIC: 0.25 μg mL) and cytotoxic activity against MCF-7 cancer cell lines. Compounds 1a-1l were exhibited low cytotoxicity activity compared to the standard doxorubicin (LC: 21.05 ± 0.82 μg mL). To further support the discovery of new active antibacterial agents, compounds 1g and 1b and proteins 1AJ0 and 1AI9 were examined using the AutoDock Vina program and were compared with the standards ciprofloxacin and clotrimazole. With the 1AJ0 protein, compound 1g had a higher docking score (-3.7 kcal mol) than ciprofloxacin (-5.6 kcal mol), and with the 1AI9 protein, compound 1b had a higher docking score (-4.8 kcal mol) than clotrimazole (-4.4 kcal mol). Additionally, molecular dynamics simulation was used to investigate the most probable binding mode of compounds 1b and 1g with 1AI9 and 1AJ0, respectively. The -FeO-CuO catalyst was used to prepare pyrazolo[3,4-]pyrazole derivatives, which were successfully characterized and screened for antimicrobial and cytotoxic activities, molecular docking, and molecular dynamics simulation studies.
在本研究中,我们开发了一种具有抗菌和抗真菌活性的新型吡唑并[3,4 - ]吡唑衍生物,其在治疗传染病方面显示出巨大潜力。为了评估1AJ0和1AI9蛋白对开发强效抗菌和抗真菌化合物的结合亲和力,我们使用()叶提取物作为封端和还原剂,并使其与FeO和Cu(OAc)溶液反应以合成 -FeO-CuO纳米催化剂。使用傅里叶变换红外光谱、透射电子显微镜、紫外 - 可见光谱和X射线衍射分析对新合成的化合物进行了确认。抗菌筛选显示,化合物1g对(MIC:1μg mL)具有高活性,并且比标准环丙沙星更有效。化合物1b对(MIC:0.25μg mL)显示出比克霉唑更高的抗真菌活性以及对MCF - 7癌细胞系的细胞毒性活性。与标准阿霉素(LC:21.05±0.82μg mL)相比,化合物1a - 1l表现出低细胞毒性活性。为了进一步支持新型活性抗菌剂的发现,使用AutoDock Vina程序对化合物1g和1b以及蛋白1AJ0和1AI9进行了检查,并与标准环丙沙星和克霉唑进行了比较。对于1AJ0蛋白,化合物1g的对接分数(-3.7 kcal mol)高于环丙沙星(-5.6 kcal mol),对于1AI9蛋白,化合物1b的对接分数(-4.8 kcal mol)高于克霉唑(-4.4 kcal mol)。此外,分子动力学模拟用于分别研究化合物1b和1g与1AI9和1AJ0最可能的结合模式。 -FeO-CuO催化剂用于制备吡唑并[3,4 - ]吡唑衍生物,对其进行了成功表征,并针对抗菌和细胞毒性活性、分子对接以及分子动力学模拟研究进行了筛选。